# EDGAR Filing Document

**Accession Number:** 0000887359
**File Stem:** 0001140361-26-018538
**Filing Date:** 2026-5
**Character Count:** 6830
**Document Hash:** a390dcb5ec3fd58d194dc638b247f44d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-018538.hdr.sgml**: 20260501

**ACCESSION NUMBER**: 0001140361-26-018538

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260429

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260501

**DATE AS OF CHANGE**: 20260501

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vericel Corp
- **CENTRAL INDEX KEY:** 0000887359
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943096597
- **STATE OF INCORPORATION:** MI
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35280
- **FILM NUMBER:** 26932434

**BUSINESS ADDRESS:**
- **STREET 1:** 64 SIDNEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 7349305555

**MAIL ADDRESS:**
- **STREET 1:** 64 SIDNEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AASTROM BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 19960428

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

------

Date of Report (Date of Earliest Event Reported): **April 29, 2026**

## Vericel Corporation
(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Michigan**<br>| **001-35280**<br>| **94-3096597**<br>|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **64 Sidney Street**  |  |
| **Cambridge, MA** | **02139**  |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(617) 588-5555**

#### Not Applicable
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, no par value<br>| VCEL<br>| NASDAQ<br>|

---

Indicate by a check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
|  **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

At the Annual Meeting of Shareholders held on April 29, 2026 (the "Annual Meeting"), the shareholders of Vericel Corporation, a Michigan corporation (the "Company"), voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission ("SEC") on March 19, 2026: (i) the election of each of Robert Zerbe, Alan Rubino, Heidi Hagen, Kevin McLaughlin, Paul Wotton, Lisa Wright and Dominick Colangelo as a director of the Company to serve for a one-year term expiring at the Company's 2027 annual meeting of shareholders and until his or her successor has been elected and qualified ("Proposal 1"), (ii) the approval, on a non-binding advisory basis, of the compensation of the named executive officers of the Company ("Proposal 2"), and (iii) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 ("Proposal 3").

The Company's shareholders approved the nominees recommended for election in Proposal 1 at the Annual Meeting.

Shareholders voted for directors as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **For** | **Abstain/Withheld** | **Broker Non-Votes** |
| Robert Zerbe | 42191350 | 3914396 | 2162887 |
|  Alan Rubino | 41344254 | 4761492 | 2162887 |
| Heidi Hagen | 38296679 | 7809067 | 2162887 |
|  Kevin McLaughlin | 44940402 | 1165344 | 2162887 |
| Paul Wotton | 43727059 | 2378687 | 2162887 |
|  Lisa Wright | 45198344 | 907402 | 2162887 |
|  Dominick Colangelo | 45035568 | 1070178 | 2162887 |

---

The Company's shareholders approved, on a non-binding advisory basis, Proposal 2 concerning the compensation of the Company's named executive officers. The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 36,350,150 | 9,725,057 | 30,539 | 2,162,887 |

---

The Company's shareholders approved Proposal 3 to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026. The votes cast at the Annual Meeting were as follows:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 44,971,340 | 3,275,442 | 21,851 |

---

---

| | |
|:---|:---|
|  **Item 9.01** | **Financial Statements and Exhibits** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL) |

---

------

#### EXHIBIT INDEX

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Vericel Corporation** | **Vericel Corporation** |
| Date: May 1, 2026 | By: | /s/ Sean C. Flynn |
|  |  | Name: Sean C. Flynn |
|  |  | Title: Chief Legal Officer |

---

------